Bio-Techne Corp

TECH

Equity

ISIN US09073M1045 / Valor 25995847

NASDAQ (2024-11-20)

USD 68.72+3.54%

Bio-Techne Corp
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

Bio-Techne Corp is a global company that specializes in providing a wide range of products in the fields of hematology, chemistry, immunology, and measurement of blood gases. Through strategic acquisitions, the company has expanded its offerings to include monoclonal and polyclonal antibodies, antigens, and other biological reagents, as well as innovative ubiquitin-related research products. With a product line extending to over 24,000 items, Bio-Techne Corp focuses on serving the diagnostics industry by offering a comprehensive catalog of high-quality products, with 95% of them manufactured in-house.

Summarized from source with an LLMView SourceSector: Technology

Fourth Quarter Revenue

Bio-Techne Corp reported a 2% increase in net sales for the fourth quarter of fiscal 2024, reaching $306.1 million. Organic revenue saw a 1% rise, with acquisitions contributing an additional 1%. Foreign currency exchange and a business held-for-sale did not materially impact these results.

GAAP Earnings

For the fourth quarter of fiscal 2024, Bio-Techne Corp's GAAP earnings per share (EPS) was $0.25, a decrease from $0.47 in the same quarter last year. GAAP operating income dropped 52% to $45.8 million, compared to $94.5 million in the fourth quarter of fiscal 2023, with a GAAP operating margin of 15.0%.

Non-GAAP Earnings

Bio-Techne Corp's adjusted EPS for the fourth quarter of fiscal 2024 was $0.49, down from $0.55 in the same period last year. Adjusted operating income decreased by 9% to $101.8 million, with an adjusted operating margin of 33.5%, compared to 37.1% in the fourth quarter of fiscal 2023.

Full Year Revenue

For the full fiscal year 2024, Bio-Techne Corp reported a 2% increase in net sales, totaling $1.2 billion. Organic revenue grew by 1%, with acquisitions contributing another 1%. The company experienced a favorable impact from foreign currency exchange.

Full Year GAAP Earnings

Bio-Techne Corp's GAAP EPS for the full fiscal year 2024 was $1.05, down from $1.76 in the previous year. GAAP operating income decreased by 31% to $206.7 million, with a GAAP operating margin of 17.8%, compared to 26.3% in fiscal 2023.

Summarized from source with an LLMView Source

Key figures

8.07%1Y

-86.3%3Y

-68.5%5Y

Performance

36.1%1Y

89.4%3Y

72.7%5Y

Volatility